Goserelin a GnRH-analogue as third-line therapy of refractory epithelial ovarian cancer.
Between October 1988 and March 1991, 23 ovarian cancer patients with progressive disease whilst receiving second- or third-line polychemotherapy received subcutaneously 3.6 mg Goserelin, a GnRH analogue, at monthly intervals until further tumor progression. Four patients (17.4%) achieved partial response, 7 patients (30.4%) had stable disease and 12 patients (52.2%) showed further tumor progression. Median time to tumor progression was 8.5, 5.3 and 2.1 months, respectively (Mantel test, P = 0.0003). Ten out of 11 patients who showed partial response or no change had grade 2 or grade 3 tumors. We conclude that Goserelin shows evidence of antitumor activity also in grade 2 and grade 3 ovarian carcinoma. It offers a therapeutic alternative to a group of patients, in whom we usually terminate cytotoxic treatment.
Sevelda
P.
P
Oncologic Unit of the 1st Department of Gynecology & Obstetrics, University of Vienna and Department of Chemotherapy, University of Vienna, Austria.
Vavra
N.
N
Fitz
R.
R
Barrada
M.
M
Salzer
H.
H
Baur
M.
M
Dittrich
C.
C